Clinical Trial Update: Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A combined phase 1/2 trial of pomalidomide, dexamethasone, and filgrastim-sndz in relapsed or refractory multiple myeloma has been terminated with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light Chain Multiple Myeloma
• Multiple Myeloma
• Plasma Cell Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Filgrastim-sndz (filgrastim-sndz)
• Pomalidomide (Pomalidomide)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Multiple Myeloma-Light Chain Only, Recurrent Plasma Cell Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-07-30